We're taking Memorial Day off

FierceBiotech and its sister publications won't be publishing Monday as we observe Memorial Day. Our three daily publications and the usual Monday weeklies, FierceCRO (subscribe) and FierceBiotechIT (subscribe), will be sent to you on Tuesday, May 28. You will also receive FierceBiotechResearch (subscribe) and FiercePharmaManufacturing (subscribe) on Tuesday as usual.

FierceBiotech, FiercePharma, FierceMedicalDevices and FierceDrugDelivery each published a new special report this week:

  • Top 10 Biotech CEO Pay Packages of 2012
  • 20 Highest-Paid Biopharma CEOs of 2012
  • 2013's biggest job-cutters in medical devices and diagnostics (so far)
  • The Future of Nanotech Drug Delivery

Enjoy the long weekend! -- Jennifer Levin (email | Twitter)

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.